In addition to the acute symptoms of travelers' diarrhea, which include severe diarrhea, abdominal cramps and dehydration, patients who suffer a bout of travelers' diarrhea are also at higher risk of developing irritable bowel syndrome, a chronic condition characterized by pain, bloating, diarrhea or constipation.
Diarrheal disease also exacts a significant toll on children in the developing world, where diarrhea linked to enterotoxigenic E. coli -- the most common causes of travelers' diarrhea -- sickens 210 million children each year, killing more than 350,000 annually.
"Bacterial diarrheal disease is a significant medical problem for children and travelers, and our technology represents an advance in vaccine delivery and a breakthrough in the field of infectious disease. We look forward to targeting both the significant travelers market and developing the vaccine for the children in the developing world who still suffer serious morbidity and mortality from this disease," said Gregory Glenn, M.D., Iomai's Chief Scientific Officer.
Iomai plans to initiate a Phase III program for the needle-free vaccine patch in 2009.
The research was conducted in collaboration with researchers from the Johns Hopkins Bloomberg School of Public Health and the University of Texas School of Public Health.
The Lancet, which has been published since 1823, is an independent and authoritative voice in global medicine that seeks to publish high-quality clinical trials that will alter medical practice. The Lancet delivers in-depth knowledge in key medical disciplines. (http://www.thelancet.com)
About the Phase II Trek Study
The Trek Study followed travelers to Mexico and Guatemala. Volunteers
received either two doses of the Iomai vaccine patch or a placebo, 2 to 3
weeks apart, with the last dose administered at least a week before travel.
Travelers kept detailed dia
|SOURCE Iomai Corporation|
Copyright©2008 PR Newswire.
All rights reserved